Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Duchenne Muscular Dystrophy Drugs market report explains the definition, types, applications, major countries, and major players of the Duchenne Muscular Dystrophy Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Debiopharm International SA
Strykagen Corp
FibroGen Inc
Biophytis SAS
Beech Tree Labs Inc
Akashi Therapeutics Inc
Santhera Pharmaceuticals Holding AG
SOM Biotech SL
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Antisense Therapeutics Ltd
Fulcrum Therapeutics Inc
CRISPR Therapeutics
WAVE Life Sciences Ltd
Genethon SA
Eloxx Pharmaceuticals Inc
Biogen Inc
Capricor Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Catabasis Pharmaceuticals Inc
Sarepta Therapeutics Inc
BioMarin Pharmaceutical Inc
Teijin Pharma Ltd
Summit Therapeutics Plc
Editas Medicine Inc
F Hoffmann-La Roche Ltd
Galapagos NV
GTx Inc
Bioleaders Corp
By Type:
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
By End-User:
Hospitals and Clinics
Medical Laboratories
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Duchenne Muscular Dystrophy Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Duchenne Muscular Dystrophy Drugs Outlook to 2028- Original Forecasts
-
2.2 Duchenne Muscular Dystrophy Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Duchenne Muscular Dystrophy Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Duchenne Muscular Dystrophy Drugs Market- Recent Developments
-
6.1 Duchenne Muscular Dystrophy Drugs Market News and Developments
-
6.2 Duchenne Muscular Dystrophy Drugs Market Deals Landscape
7 Duchenne Muscular Dystrophy Drugs Raw Materials and Cost Structure Analysis
-
7.1 Duchenne Muscular Dystrophy Drugs Key Raw Materials
-
7.2 Duchenne Muscular Dystrophy Drugs Price Trend of Key Raw Materials
-
7.3 Duchenne Muscular Dystrophy Drugs Key Suppliers of Raw Materials
-
7.4 Duchenne Muscular Dystrophy Drugs Market Concentration Rate of Raw Materials
-
7.5 Duchenne Muscular Dystrophy Drugs Cost Structure Analysis
-
7.5.1 Duchenne Muscular Dystrophy Drugs Raw Materials Analysis
-
7.5.2 Duchenne Muscular Dystrophy Drugs Labor Cost Analysis
-
7.5.3 Duchenne Muscular Dystrophy Drugs Manufacturing Expenses Analysis
8 Global Duchenne Muscular Dystrophy Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Duchenne Muscular Dystrophy Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Duchenne Muscular Dystrophy Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Duchenne Muscular Dystrophy Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Development & Drug Target Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Mechanism of Action (MoA) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Route of Administration (RoA) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Molecule Type Consumption and Growth Rate (2017-2022)
-
9.2 Global Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Medical Laboratories Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Duchenne Muscular Dystrophy Drugs Market Analysis and Outlook till 2022
-
10.1 Global Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.2.2 Canada Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.2.3 Mexico Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.2 UK Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.3 Spain Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.4 Belgium Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.5 France Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.6 Italy Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.7 Denmark Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.8 Finland Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.9 Norway Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.10 Sweden Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.11 Poland Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.12 Russia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.3.13 Turkey Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.2 Japan Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.3 India Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.4 South Korea Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.8 Thailand Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.9 Singapore Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.11 Philippines Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.2 Colombia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.3 Chile Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.4 Argentina Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.6 Peru Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6.3 Oman Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6.4 Qatar Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.7.2 South Africa Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.7.3 Egypt Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.7.4 Algeria Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)
11 Global Duchenne Muscular Dystrophy Drugs Competitive Analysis
-
11.1 Debiopharm International SA
-
11.1.1 Debiopharm International SA Company Details
-
11.1.2 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.1.4 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Strykagen Corp
-
11.2.1 Strykagen Corp Company Details
-
11.2.2 Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.2.4 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 FibroGen Inc
-
11.3.1 FibroGen Inc Company Details
-
11.3.2 FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.3.4 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Biophytis SAS
-
11.4.1 Biophytis SAS Company Details
-
11.4.2 Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.4.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Beech Tree Labs Inc
-
11.5.1 Beech Tree Labs Inc Company Details
-
11.5.2 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.5.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Akashi Therapeutics Inc
-
11.6.1 Akashi Therapeutics Inc Company Details
-
11.6.2 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.6.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Santhera Pharmaceuticals Holding AG
-
11.7.1 Santhera Pharmaceuticals Holding AG Company Details
-
11.7.2 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.7.4 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 SOM Biotech SL
-
11.8.1 SOM Biotech SL Company Details
-
11.8.2 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.8.4 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Cumberland Pharmaceuticals Inc
-
11.9.1 Cumberland Pharmaceuticals Inc Company Details
-
11.9.2 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.9.4 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Daiichi Sankyo Co Ltd
-
11.10.1 Daiichi Sankyo Co Ltd Company Details
-
11.10.2 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.10.4 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Antisense Therapeutics Ltd
-
11.11.1 Antisense Therapeutics Ltd Company Details
-
11.11.2 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.11.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Fulcrum Therapeutics Inc
-
11.12.1 Fulcrum Therapeutics Inc Company Details
-
11.12.2 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.12.4 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 CRISPR Therapeutics
-
11.13.1 CRISPR Therapeutics Company Details
-
11.13.2 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.13.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 WAVE Life Sciences Ltd
-
11.14.1 WAVE Life Sciences Ltd Company Details
-
11.14.2 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.14.4 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Genethon SA
-
11.15.1 Genethon SA Company Details
-
11.15.2 Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Genethon SA Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.15.4 Genethon SA Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Eloxx Pharmaceuticals Inc
-
11.16.1 Eloxx Pharmaceuticals Inc Company Details
-
11.16.2 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.16.4 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Biogen Inc
-
11.17.1 Biogen Inc Company Details
-
11.17.2 Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.17.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 Capricor Therapeutics Inc
-
11.18.1 Capricor Therapeutics Inc Company Details
-
11.18.2 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.18.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Taiho Pharmaceutical Co Ltd
-
11.19.1 Taiho Pharmaceutical Co Ltd Company Details
-
11.19.2 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.19.4 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Catabasis Pharmaceuticals Inc
-
11.20.1 Catabasis Pharmaceuticals Inc Company Details
-
11.20.2 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.20.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 Sarepta Therapeutics Inc
-
11.21.1 Sarepta Therapeutics Inc Company Details
-
11.21.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.21.4 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 BioMarin Pharmaceutical Inc
-
11.22.1 BioMarin Pharmaceutical Inc Company Details
-
11.22.2 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.22.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.22.5 Recent Research and Development Strategies
-
11.23 Teijin Pharma Ltd
-
11.23.1 Teijin Pharma Ltd Company Details
-
11.23.2 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.23.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.23.4 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.23.5 Recent Research and Development Strategies
-
11.24 Summit Therapeutics Plc
-
11.24.1 Summit Therapeutics Plc Company Details
-
11.24.2 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.24.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.24.4 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.24.5 Recent Research and Development Strategies
-
11.25 Editas Medicine Inc
-
11.25.1 Editas Medicine Inc Company Details
-
11.25.2 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.25.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.25.4 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.25.5 Recent Research and Development Strategies
-
11.26 F Hoffmann-La Roche Ltd
-
11.26.1 F Hoffmann-La Roche Ltd Company Details
-
11.26.2 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.26.3 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.26.4 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.26.5 Recent Research and Development Strategies
-
11.27 Galapagos NV
-
11.27.1 Galapagos NV Company Details
-
11.27.2 Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.27.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.27.4 Galapagos NV Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.27.5 Recent Research and Development Strategies
-
11.28 GTx Inc
-
11.28.1 GTx Inc Company Details
-
11.28.2 GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.28.3 GTx Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.28.4 GTx Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.28.5 Recent Research and Development Strategies
-
11.29 Bioleaders Corp
-
11.29.1 Bioleaders Corp Company Details
-
11.29.2 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.29.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
11.29.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Portfolio
-
11.29.5 Recent Research and Development Strategies
12 Global Duchenne Muscular Dystrophy Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Development & Drug Target Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Mechanism of Action (MoA) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Route of Administration (RoA) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Molecule Type Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Duchenne Muscular Dystrophy Drugs Market Analysis and Outlook to 2028
-
13.1 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Duchenne Muscular Dystrophy Drugs
-
Figure of Duchenne Muscular Dystrophy Drugs Picture
-
Table Global Duchenne Muscular Dystrophy Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Duchenne Muscular Dystrophy Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Development & Drug Target Consumption and Growth Rate (2017-2022)
-
Figure Global Mechanism of Action (MoA) Consumption and Growth Rate (2017-2022)
-
Figure Global Route of Administration (RoA) Consumption and Growth Rate (2017-2022)
-
Figure Global Molecule Type Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Medical Laboratories Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Table North America Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure United States Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure Germany Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure China Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure Brazil Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)
-
Figure Australia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Debiopharm International SA Company Details
-
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Strykagen Corp Company Details
-
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table FibroGen Inc Company Details
-
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Biophytis SAS Company Details
-
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Beech Tree Labs Inc Company Details
-
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Akashi Therapeutics Inc Company Details
-
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Santhera Pharmaceuticals Holding AG Company Details
-
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table SOM Biotech SL Company Details
-
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Cumberland Pharmaceuticals Inc Company Details
-
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Daiichi Sankyo Co Ltd Company Details
-
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Antisense Therapeutics Ltd Company Details
-
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Fulcrum Therapeutics Inc Company Details
-
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table CRISPR Therapeutics Company Details
-
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table WAVE Life Sciences Ltd Company Details
-
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Genethon SA Company Details
-
Table Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genethon SA Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Genethon SA Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Eloxx Pharmaceuticals Inc Company Details
-
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Biogen Inc Company Details
-
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Capricor Therapeutics Inc Company Details
-
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Taiho Pharmaceutical Co Ltd Company Details
-
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Catabasis Pharmaceuticals Inc Company Details
-
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Sarepta Therapeutics Inc Company Details
-
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table BioMarin Pharmaceutical Inc Company Details
-
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Teijin Pharma Ltd Company Details
-
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Summit Therapeutics Plc Company Details
-
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Editas Medicine Inc Company Details
-
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table F Hoffmann-La Roche Ltd Company Details
-
Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Galapagos NV Company Details
-
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table GTx Inc Company Details
-
Table GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GTx Inc Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table GTx Inc Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Table Bioleaders Corp Company Details
-
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Main Business and Markets Served
-
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Portfolio
-
Figure Global Development & Drug Target Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Mechanism of Action (MoA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Route of Administration (RoA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Molecule Type Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
